UPDATE – Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public Platform

Glucotrack, Inc. (Nasdaq: GCTK) today announced the completion of its strategic business combination with Lōkahi Therapeutics, establishing a publicly listed, capital-efficient platform for the identification, acquisition, and advancement of differentiated healthcare assets. The transaction is structured such that Lōkahi Therapeutics becomes the operating and controlling business of the combined company, leveraging Glucotrack’s public market platform to support long-term growth and access to capital. The combined organization integrates Lōkahi Therapeutics’ dual-engine model - its late-stage clinical development program and ai²-driven asset sourcing and advancement platform - with Glucotrack’s existing technology infrastructure to create a scalable, repeatable framework for value creation. In connection with the closing, Lōkahi Therapeutics securityholders received a combination of Glucotrack common stock and convertible preferred stock. Upon receipt of required stockholder approvals and satisfaction of applicable Nasdaq listing requirements, the preferred stock is expected to convert into common equity, resulting in Lōkahi Therapeutics securityholders holding approximately 90% of the combined company on a fully diluted basis, subject to transaction-related financing and customary adjustments. E.F. Hutton & Co. served as exclusive financial advisor in the strategic business combination between Glucotrack, Inc. and Lōkahi Therapeutics. The transaction is supported by a planned private placement financing designed to strengthen the combined company’s capital position and support near-term execution. A designated portion of the proceeds is expected to be allocated to support the continued development and operation of Glucotrack’s legacy continuous blood glucose monitoring (CBGM) technology within a dedicated subsidiary structure. Glucotrack’s CBGM business will operate as a wholly owned subsidiary of the combined company, with its operations, assets, and capital structure maintained separately to enable focused execution and strategic flexibility. Erik Emerson has been appointed Chief Executive Officer of the combined company, providing unified leadership across the organization. Paul Goode will serve as Chief Technical Officer of the combined company and Chief Executive Officer of the CBGM subsidiary. “This transaction establishes a capital-efficient, publicly listed platform designed to systematically identify, acquire, and advance differentiated healthcare assets,” said Erik Emerson, Chief Executive Officer. “By combining public market access with Lōkahi Therapeutics’ ai² platform and disciplined operating model, we are positioned to expand our pipeline, strengthen our capital structure, and pursue a broader set of strategic opportunities.” Paul Goode, Chief Technical Officer, added: “This combination enables the continued advancement of Glucotrack’s core technology within a focused operating structure while participating in a broader platform designed for scalable growth. We believe this integrated approach supports disciplined execution across both operating priorities.” About Lōkahi Therapeutics Lōkahi Therapeutics is a capital-efficient biopharmaceutical platform company focused on identifying, evaluating, acquiring, and advancing overlooked therapeutic assets. Through its ai² platform and ai² Futures Lab execution model...